Medtronic PLC $MDT Shares Purchased by Monte Financial Group LLC

Monte Financial Group LLC increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 32.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,668 shares of the medical technology company’s stock after buying an additional 10,546 shares during the quarter. Monte Financial Group LLC’s holdings in Medtronic were worth $4,064,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its holdings in Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares during the period. Sivia Capital Partners LLC increased its position in shares of Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after acquiring an additional 381 shares in the last quarter. Perigon Wealth Management LLC increased its position in shares of Medtronic by 8.0% in the second quarter. Perigon Wealth Management LLC now owns 14,831 shares of the medical technology company’s stock worth $1,293,000 after acquiring an additional 1,096 shares in the last quarter. Kathmere Capital Management LLC raised its stake in shares of Medtronic by 29.9% in the 2nd quarter. Kathmere Capital Management LLC now owns 7,772 shares of the medical technology company’s stock valued at $677,000 after acquiring an additional 1,788 shares during the period. Finally, ORG Partners LLC lifted its holdings in shares of Medtronic by 10.0% during the 2nd quarter. ORG Partners LLC now owns 2,012 shares of the medical technology company’s stock valued at $179,000 after acquiring an additional 183 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.4%

MDT stock opened at $100.98 on Monday. The company has a market capitalization of $129.45 billion, a P/E ratio of 27.22, a PEG ratio of 2.66 and a beta of 0.71. The firm has a 50 day simple moving average of $99.44 and a 200-day simple moving average of $95.32. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.8%. Medtronic’s dividend payout ratio is presently 76.55%.

Wall Street Analysts Forecast Growth

Several research firms have commented on MDT. Wells Fargo & Company raised their price objective on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Sanford C. Bernstein raised their target price on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Morgan Stanley boosted their price target on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Friday. Finally, TD Cowen reiterated a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Fourteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).